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Abstract
Background—Tyrosine kinase inhibitors (TKIs) improve survival of chronic myeloid leukemia
(CML) patients dramatically; however, non-adherence to TKI therapy may lead to resistance to the
therapy. They are very expensive and covered under Part D insurance for Medicare patients. The
impact of low-income subsidy status and cost-sharing on adherence was not well studied in the
literature among this group.
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Methods—Surveillance, Epidemiology, and End Results (SEER) registry data linked with
Medicare Part D data from years 2007–2012 was used in this study. We identified 836 CML
patients with Medicare Part D insurance coverage who were new TKI users. Treatment nonadherence was defined as a binary variable indicating proportion of days covered (PDC) lower
than 80% during the 180-day period after TKI therapy initiation. Logistic regression was used to
examine the relationship between out of pocket (OOP) cost per 30-day drug supply, Part D plan
characteristics and treatment adherence while controlling for other patient characteristics.
Results—Overall 244 (29%) of the 836 CML patients were non-adherent to targeted oral therapy
during the 180 days after they began taking the TKIs. The multivariable logistic regression showed
that patients with heavily subsidized (OR=6.7, 95% CI: 2.8~15.9) and moderately subsidized
(OR=3.0, 95% CI: 1.4~6.5) Part D plans were much more likely to have non-adherence than
patients without subsidy.
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Conclusions—This population-based study found a significantly higher rate of non-adherence
among heavily subsidized patients with substantially lower OOP costs, which suggests that future
research is needed to help lower the non-adherence rate among these patients.
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Adherence; TKIs; Medicare Part D; CML; SEER
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Introduction
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There have been rapid developments in targeted oral therapies for cancer in the past decade.1
For some cancer types, targeted oral anti-cancer drugs have become the standard of care.
One example is how a group of tyrosine kinase inhibitors (TKIs) including imatinib,
dasatinib, and nilotinib have transformed the treatment of chronic myeloid leukemia (CML)
patients. The survival of CML patients has improved dramatically due to the use of these
TKIs.2,3 However, loss of response (resistance) to TKI therapy remains a significant
challenge in CML treatment and results in less treatment options and worse clinical
outcomes.4 Researchers have found that poor adherence to TKI therapy is strongly
associated with loss of response and treatment failure.5,6 Oral TKIs are very expensive and
constitute a major contributing factor to the rapid rise in chemotherapy costs in the US.7 The
financial burden of TKI treatment and the negative impact of non-adherence has raised many
concerns that patients’ non-adherence, which is strongly influenced by high drug costs, may
lead to undesired clinical and economic outcomes.
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Studies have found that non-adherence to TKI treatment results in lower pharmacy costs but
much higher medical costs and higher total costs overall.8–10 There are many papers in the
literature showing that higher cost burdens on patients can lead to worse adherence to
medications.11–14 One important study on the relationship between cost sharing and
adherence to TKIs found that higher copayments were significantly associated with nonadherence.15 However, most of these studies are based on employer-sponsored insurance and
the main study populations are younger patients. CML is most frequently diagnosed among
people aged 65-74; approximately half of newly diagnosed patients are 65 years or older.16
Given the higher incidence of disease among the elderly population, it is important to
investigate the relationship between adherence and drug cost sharing for elderly CML
patients who most likely have Medicare Part D prescription plans.
Medicare Part D prescription drug benefit began in 2006 as an important component of
Medicare insurance. Under Medicare Part D, some beneficiaries receive the low-income
subsidy (LIS) and get assistance in paying for Medicare Part D prescription drug costs; they
also do not have a gap in prescription drug coverage. Eligibility and the amount of subsidy
depend on the individual’s income compared to the Federal Poverty Level and resource
limitations. In 2014, more than 11 million Medicare Part D enrollees received the LIS.17
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There have been many studies examining the relationship between LIS and medication
adherence. One paper found that adherence to diabetes medication was moderately better
among LIS beneficiaries compared to beneficiaries without subsidies.18 Another study
focused on patients’ adherence to clopidogrel after stent placement and found that
beneficiaries with LIS had better adherence.19 However, there is scarce literature on CML
patients under Medicare Part D prescription plans taking expensive oral TKI therapies.
Studies have shown that although higher cost-sharing is generally associated with reductions
in specialty drug utilization, the effects varied significantly by type of disease and specialty
drug.20 There are two important recent studies21,22 that examined TKI usage among
Medicare beneficiaries with CML. Both studies mainly focused on the initiation of TKI
therapy among newly diagnosed CML patients and both found that patients with low-income
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subsidies were more likely to initiate TKI treatment. Interestingly, the second study22 found
that despite the differences in initiation between patients with and without subsidies, once
the treatment was initiated there was no significant difference in adherence between patients
with and without subsidies. It is possible that this conclusion is partly due to the small
sample size of the study, since the analysis on adherence was based on 202 patients with
stand-alone Part D plans. Different from these two studies on newly diagnosed patients, our
study focuses on the adherence to TKI therapy among a larger group of prevalent CML
patients (836 patients) who started TKI therapy with a 6 month washout period. Our sample
included both patients with stand-alone Medicare Part D plans and patients with other Part D
plans such as Managed Care Organizations, regional Preferred Provider Organization (PPO)
and employer-sponsored plans. Further, we calculated the actual patient out-of-pocket
payment per month supply of TKI and also considered their out-of-pocket payments for
other drugs. The aim of our study is to examine the relationship between cost sharing, Part D
plan type, low-income subsidy status and adherence to oral TKI treatment among elderly
CML patients who initiated TKI therapy and have Medicare Part D prescription plans.

Author Manuscript

Methods
Data Source
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We used the Surveillance, Epidemiology, and End Results (SEER) registry data linked with
Medicare Part D data from 2007 to 2012 in this study (the newest data available at the time
of the study). The SEER registries of the National Cancer Institute (NCI) are a large data
source providing information on cancer incidence and characteristics covering
approximately 28% of the US population. The linkage to Medicare Part D data enhances the
information that is available by providing details on patients’ demographics, prescription
drug plans and drug usage.
Study Cohort
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We first selected patients diagnosed with CML on or before 2012 based on the SEER
registry cancer site information according to WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues (i.e., ICD-O-3 codes 9863, 9875-9876,
9945-9946).23 We then identified new users of any of the three TKIs that we studied
(imatinib, dasatinib, and nilotinib) by imposing a wash-out period of at least 6 months
without any use of the above TKIs. To ensure complete Medicare claims to capture their
prescription drug usage, we restricted the sample to include patients with continuous
enrollment in one type of prescription plan (either a traditional stand-alone Part D plan,
regional PPO plan, Managed Care Organizations other than Regional PPO, or employersponsored plan throughout) during the 6 months before and 6 months after the start of the
TKI therapy. We further required that the patients’ prescription plans and subsidy and
copayment status did not change throughout this time period. Finally, we excluded patients
with missing demographic information. The final study cohort included 836 patients for
analysis. The detailed inclusion and exclusion steps of our study cohort are provided in
Table 1.
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We examined non-adherence to TKI therapy during the 6 months after the start of the
therapy. We defined non-adherence as a binary variable indicating that the proportion of
days covered (PDC) was lower than 80%.24 In other words, patients were considered nonadherent if the number of days of TKI supply covered less than 80% of days for the patient
during the 180-day period after the initiation of TKI therapy. We did not exclude
hospitalization days as TKIs are very expensive and hospitals are unlikely to include them
on the hospital formularies.25 The four key independent variables were the out-of-pocket
(OOP) cost per 30 days of supply of TKIs, OOP spent on other drugs during the 180 days,
Part D plan subsidy status, and Part D plan type. We divided the total OOP payments for
TKIs by the total days of drug supply during the 180-day period after initiation and then
multiplied it by 30 to obtain the OOP cost per 30 days of supply. All costs were inflation
adjusted to 2014 dollars based on the medical care component of the Consumer Price Index.
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We created three groups for subsidy status: a) heavily subsidized (100% premium-subsidy
with no or low copayment), b) moderately subsidized (some premium-subsidy and
copayment) and c) no subsidy. The Part D plan types were categorized into two groups: a)
traditional stand-alone Part D Plans and b) all other plans including Managed Care
Organizations (MCOs), Regional Preferred Provider Organizations (RPPOs) and employersponsored plans. MCOs and RPPOs are networks of health care providers who offer
managed care health plans. MCOs usually only pay for health services within this network.
RPPOs pay for services within and outside of the network with the patients paying a higher
proportion of cost-sharing when out-of-network services were used. Employer-sponsored
plans are group insurance plans offered by employers. The employers negotiate with insurers
and often provide a range of plan options to employees.

Author Manuscript

Other Independent Variables
We included patients’ demographic information, neighborhood socioeconomic status and the
year when they started TKI therapies. The demographic characteristics included age (≤70, or
>70), sex (male, female), race (white, non-white), region (Northeast, West, Midwest, South)
and urban/rural status (metropolitan vs. non-metropolitan). The neighborhood
socioeconomic status variables included three variables in terms of quartiles: median
household income, percent living in poverty and percent with at least four years of college
education. Notice that the quartile cutoffs change every year, and we provide the cutoff
levels in the Supplementary Material.
Statistical Analyses
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We provided descriptive statistics of our study cohort. Group differences in non-adherence to
TKI therapy were tested with chi-squared statistics. For the continuous variables OOP cost
per 30 days of TKI supply and OOP payment for all other drugs, Wilcoxon-Mann-Whitney
test was used to test the difference as the cost variable is skewed. We also provide the box
plots of OOP cost per 30 days of TKI supply by subsidy status. We employed a multivariate
logistic regression to explore factors associated with non-adherence to TKIs and presented
the findings in adjusted odds ratios (ORs) and their corresponding 95% confidence intervals
(CIs). As patients with subsidies and patients without subsidies are likely to be two very
Cancer. Author manuscript; available in PMC 2019 January 15.
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different groups and respond to factors differently, we also conducted subgroup analyses for
these two groups. All statistical analyses were conducted in SAS 9.3 (SAS Institute, Cary
NC). This study received exemption status from the Institutional Review Board at The
University of Texas MD Anderson Cancer Center.

Results

Author Manuscript

Table 2 provides detailed descriptive statistics of the study cohort. Overall 244 (29%) out of
the 836 CML patients were non-adherent to TKIs during the 180 days after drug initiation.
Patients with heavily subsidized plans were significantly (p-value=0.036) much more likely
to be non-adherent. It is interesting that a much higher percentage of patients with heavily
subsidized plans were non-adherent compared to patients with no subsidy (36% vs. 27%,
respectively), while patients with moderately subsidized plans had less non-adherence
(25%). In terms of OOP cost per 30 days of TKI supply, the non-adherent individuals had
higher cost (mean $829 vs $567; p-value=0.005).
We also analyzed the OOP costs per 30 days of TKI supply by subsidy status. The box plot
(Figure 1) shows the substantial difference in OOP costs for patients based on subsidy status.
Patients who are heavily subsidized have very low OOP costs with a median of $1.3 per 30
days of TKI supply and an interquartile range of $1.3; the moderately subsidized group also
had low OOP costs with a median of $3.0 and an interquartile range of $3.6; the group
without subsidy had much higher OOP costs with a median of $980.7 and an interquartile
range of $668.6. When taken together, our findings suggest that while patients who were
heavily subsidized had low OOP costs, their drug adherence was worse than that of
individuals in the moderately subsidized or no subsidy groups.

Author Manuscript
Author Manuscript

Table 3 presents the results from the logistic regression for the whole cohort. Adjusted for all
factors included in the model, the regression still showed that the heavily subsidized group
was much more likely to be non-adherent compared with the non-subsidized group with
adjusted odds ratio of 6.69 (95% CI: 2.81~15.9). Moderately subsidized patients were also
more likely to have non-adherence (OR=2.99, 95% CI: 1.38~6.46) than patients without
subsidy. Unsurprisingly, controlling for all other factors, patients with higher OOP payments
per 30 days of supply were more likely to have TKI medication non-adherence issues
compared to individuals with lower OOP payments. The odds ratio associated with a
doubling of OOP costs per 30 days of supply was 1.12 (95% CI: 1.02~1.22); the
corresponding odds ratio for OOP costs for other drugs was 1.1 (95% CI: 1.01~1.19). None
of the residence related variables (i.e., urban/rural status, region, and neighborhood
socioeconomic status variables) were significantly associated with non-adherence to TKI
therapy. Table 3 also includes results when the model excludes the OOP cost variables. After
excluding the two cost variables, the magnitude of association between heavy subsidy and
non-adherence reduced significantly (OR=1.7, 95% CI: 1.13~2.55); and the association
between moderate subsidy and non-adherence became insignificant.
Table 4 presents the subgroup analyses for patients with and without subsidies using a
multivariable logistic model. The analyses showed different effects of various factors in
these two subgroups. For example, in the subgroup without subsidies, older patients (greater
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than 70 years old vs 70 and below) were more likely to be non-adherent (OR=1.86, 95% CI:
1.2~2.88) while in the subgroup with subsidies, older patients had an odds ratio of 0.86
albeit statistically insignificant. In the subgroup without subsidies, patients with a Medicare
prescription drug plan (PDP) were significantly associated with lower likelihood of nonadherence (OR=0.63, 95% CI: 0.4~0.99); in the subgroup with subsidies, the association
was opposite albeit insignificant.

Author Manuscript

Even among patients with subsidies, patients with heavily subsidized plans were much more
likely (OR=3.51, 95% CI: 1.73~7.13) to be non-adherent than those with moderately
subsidized plans. Higher OOP costs (i.e., a doubling of the costs) per 30 days of TKI drug
supply, even in the subgroup with subsidies, were associated with a higher likelihood of nonadherence (OR=1.32, 95% CI: 1.08~1.62); the corresponding odds ratio associated with a
doubling of OOP spending on other drugs was 1.06 (95% CI: 0.93~1.22), a result that is
statistically insignificant. Higher OOP costs were also associated with a higher likelihood of
non-adherence among the subgroup without subsidies. The odds ratio associated with a
doubling of OOP costs per 30 days of TKI supply was 1.09 (95% CI: 0.98~1.2); the
corresponding odds ratio associated with a doubling of OOP spending on other drugs was
1.11 (95% CI: 0.99~1.24). The two OOP cost variables for the subgroup without subsidies
were not individually significant, but were jointly significant with a p-value of 0.0021.
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We also examined the percentage of patients having a predicted probability of nonadherence to TKI therapy above 50% (i.e., those more likely to be non-adherent than not)
based on these subgroup analyses results. The models predicted that the percentage of
patients who are more likely to be non-adherent than not are 5% (without subsidy group) vs
15% (with subsidy group); this large difference further confirms the importance of subsidy
status on TKI therapy adherence.

Discussion

Author Manuscript

Using SEER registry data linked with Medicare Part D claims from 2007-2012, we
examined the relationship between patient cost sharing, subsidy status and non-adherence to
targeted oral therapies among CML patients. We found that the OOP cost per 30 days of
TKI drug supply was a strong predictor for non-adherence to TKI therapy. Patients with
higher OOP costs were much more likely to have non-adherence issues. This has important
implications as non-adherence to oral TKIs may lead to severe consequences from both
clinical and economic perspectives.4–6,8–10 These findings are consistent with the body of
literature on adherence to TKIs and OOP costs. In particular, another study15 based on CML
patients under private insurance also found that patients with higher copayments were more
likely to be non-adherent. However, patients under private insurance and patients under
Medicare Part D plans have different characteristics. Patients under Medicare are older and
Medicare Part D plans usually require both copayment and coinsurance rather than
copayment alone, and OOP costs are higher because of the high price of the TKI drugs.
Indeed, we found that CML patients under Medicare Part D in our study had much higher
OOP costs for a 30-day supply of TKIs and the non-adherence rate was also much higher.
More specifically, the median OOP cost for 30 days of supply was $452 in our cohort
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compared with the $30 median copayment for the privately insured patients in that study; the
corresponding non-adherence rates were 29% compared with 23%, respectively.
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Further, after controlling for OOP costs and other patient characteristics, we found that
Medicare Part D beneficiaries with subsidies were much more likely to be non-adherent.
Given the eligibility criteria for subsidies, the patients with subsidies had lower income and
less economic resources. Many studies for different patient populations have shown that
lower income and less economic resources is significantly associated with worse medication
adherence. One systematic review26 on breast cancer showed that lower socioeconomic
status was significantly associated with lower adherence to endocrine therapy. A Brazilian
single-center study on CML patients found better adherence to TKIs among patients with
higher socioeconomic status.27 A recent study by Winn et al focusing on TKI initiation
within 180 days after CML diagnosis and subsequent TKI therapy adherence found an
insignificant difference in adherence rates based on subsidy status; instead, higher initiation
rates were identified for individuals with cost-sharing subsidies.22 In stark contrast, our
study shows that despite substantially lower OOP costs for patients with LIS status, this
population still had difficulty adhering to the TKIs. It is possible that the discrepancy in the
findings is due to the inclusion of OOP costs into our analyses which separated the impact of
subsidy on OOP costs out. Indeed, we found that if we excluded the OOP cost variables, the
association between subsidy status and non-adherence was lowered significantly. Another
explanation is the bigger sample size in our study focusing on patients who had initiated TKI
therapy, resulting in 836 patients in our sample compared to 202 in the study by Winn and
colleagues.
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There is a vast literature on the various factors related to non-adherence to oral anticancer
medications.28,29 One paper on adherence to oral TKIs among CML patients showed that
there is a complex interplay of factors that influence adherence including clinical benefits,
side effects, economic burden, functional status, patient knowledge and beliefs, physician
interactions, lifestyle factors, behavioral management, and family support.30 Another study
on CML patients in Italy found that social support, satisfaction with information received
and concomitant drug burden have significant impact on adherence to imatinib therapy.31
Some studies have shown that there can be associations between number of physician visits
and the adherence to oral anticancer medications. On the one hand, more follow-up visits
may help improve adherence;32,33 on the other hand, nonadherence may lead to higher
number of physician visits.34,35 To examine the association between number of physician
visits and nonadherence among patients, we identified a subgroup of patients who had
continuous Medicare Parts A and B enrollment and no Health Management Organization
(HMO) enrollment during the 6 months after TKI initiation to ensure completeness of
medical claims. For this subgroup, we calculated the number of outpatient visits during the 6
months based on the medical claims. We found no statistically significant difference (t-test
p-value=0.75) in adherence. Out of the 529 patients in this subgroup, 375 were adherent to
TKI treatment, while 154 were non-adherent. The mean numbers of visits were 22.79 and
23.16 for the adherent and non-adherent group, respectively, and standard deviations were:
11.89 vs. 12.14. Therefore, it is likely that many of these other factors such as social support,
health literacy, patient mental conditions and relationship with oncologists played a more
prominent role in the higher non-adherence among patients who received low-income
Cancer. Author manuscript; available in PMC 2019 January 15.
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subsidies. For example, some of these patients may have had worse functional status,
inadequate knowledge about the adverse impact of non-adherence to TKI therapy, less than
satisfactory physician interactions, poor behavior management and little family support. The
fact that the lower OOP costs did not completely mediate the impact of lower socioeconomic
status on non-adherence implies that future strategies to promote better adherence to oral
TKIs and reduce socioeconomic disparities should consider many dimensions other than
reducing the OOP cost burden on patients. Studies have shown that educational, behavioral,
affective, and multidimensional interventions improve adherence to medications.28,36 Focus
group studies or surveys, and interventional studies improving social support and patient
education among CML patients would be interesting future research directions.
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This study is based on SEER registry data linked with Medicare Part D claims, and therefore
was constrained by the availability and accuracy of the information available in registry and
claims data. For example, some of the adverse side effects of TKIs, such as rash and
headache, are difficult to capture in claims data. Therefore, we were not able to assess the
impact of adverse effects on adherence. If patients received free TKIs through patient
assistance programs, it would not be captured in the Medicare insurance claims. There are
many charity foundations that help patients receive anticancer medications.37–39 Therefore,
the adherence rate may be underestimated. Because the healthcare system in the U.S. is
different from the rest of world, some of the results in this paper may not apply to other
countries. However, one major finding of this study is that CML patients with less financial
means still have much lower adherence even when they are heavily subsidized (and hence
have very low out-of-pocket costs for the TKIs). Such a finding should have relevance to
other countries even if they have universal health coverage and relatively low out-of-pocket
costs. Nevertheless, to the best of our knowledge, the current study is the first in the
literature to examine the impact of cost sharing on drug adherence among CML patients
under Medicare Part D plans. We confirmed the impact of OOP costs on adherence, and
found that patients with subsidies had much worse adherence. Our results indicate the urgent
need to find ways in which adherence to TKIs, an important drug class that is a first-line
treatment for CML, can be improved among low-income patients with limited economic
resources.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Out of pocket cost per 30 days of targeted drug supply by subsidy status.
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Author Manuscript

Derivation of the Study Cohort
Step

Criteria

No. of observations

1

Patients diagnosed with CML on or before 2012

2

Patients who took TKI drug (Gleevec/Sprycel/Tasigna) in 2007-2012

3
4

No. Excluded

15082
2496

12586

Patients continuously enrolled in a Part D plan for 6 months before the start of the targeted
drug, and without any target drug usage within this period (6 months washout period)

970

1526

Patients continuously enrolled in a Part D plan during the 6 months after the start of targeted
drug

836

134
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Table 2

Author Manuscript

Description of the Study Sample by Adherence
Covariates

Non-adherence

Adherence

Overall

244 (29.19%)

592 (70.81%)

P value

0.121

Cohort year
2007

31 (39.74%)

47 (60.26%)

2008

58 (33.33%)

116 (66.67%)

2009

45 (26.63%)

124 (73.37%)

2010

47 (24.48%)

145 (75.52%)

2011

Masked*

129 (70.88%)

2012

Masked*

31 (75.61%)
0.489

Sex

Author Manuscript

Male

123 (28.15%)

314 (71.85%)

Female

121 (30.33%)

278 (69.67%)

70 or younger

105 (26.58%)

290 (73.42%)

older than 70

139 (31.52%)

302 (68.48%)

0.117

Age

0.648

Race
White

200 (28.86%)

493 (71.14%)

Non-white

44 (30.77%)

99 (69.23%)

Metropolitan

211 (29.63%)

501 (70.37%)

Non-metropolitan

33 (26.61%)

91 (73.39%)

0.495

Urban/rural status

0.191

Region

Author Manuscript

Northeast

32 (26.89%)

87 (73.11%)

Midwest

25 (24.04%)

79 (75.96%)

South

59 (26.58%)

163 (73.42%)

West

128 (32.74%)

263 (67.26%)

Medicare Prescription Drug Plan (PDP)

158 (28.42%)

398 (71.58%)

Managed Care Organizations or Regional PPO or Employer Sponsored

86 (30.71%)

194 (69.29%)

0.491

Plan type

0.036

Subsidy status
Heavily subsidized

71 (36.41%)

124 (63.59%)

Moderately subsidized

33 (25.38%)

97 (74.62%)

No subsidy

140 (27.40%)

371 (72.60%)
0.005

TKI drug payment per month supply ($)
Mean (standard deviation)

829 (1076)

567 (579)

Author Manuscript

0.511

Other drug payments ($)
Mean (standard deviation)

258 (558)

159 (273)
0.223

Census tract median income in quartile
First quartile

54 (25.35%)

159 (74.65%)

Second quartile

82 (32.80%)

168 (67.20%)
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Covariates

Author Manuscript

Non-adherence

Adherence

Third quartile

46 (26.14%)

130 (73.86%)

Fourth quartile

62 (31.47%)

135 (68.53%)

First quartile

65 (29.28%)

157 (70.72%)

Second quartile

57 (28.08%)

146 (71.92%)

Third quartile

69 (32.86%)

141 (67.14%)

Fourth quartile

53 (26.37%)

148 (73.63%)

P value

0.52

Census tract % below poverty level in quartile

0.565

Census tract % with at least four years of college education in quartile
First quartile

62 (28.44%)

156 (71.56%)

Second quartile

68 (26.77%)

186 (73.23%)

Third quartile

59 (32.96%)

120 (67.04%)

Fourth quartile

55 (29.73%)

130 (70.27%)

Author Manuscript

*

Masked per Surveillance, Epidemiology, and End Results-Medicare user agreement for confidentiality.
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Author Manuscript
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Logged other drug payments

Logged TKI drug payment per month supply

1.1

1.12

2.99

Moderately subsidized

No subsidy

6.69

0.73

0.97

1.26

Heavily subsidized

Cost share group

Managed Care Organizations or Regional PPO or Employer Sponsored

Medicare prescription drug plan(PDP)

Plan type

Non-white

White

Race

older than 70

70 or younger

Age

Female

Male

Sex
0.92

1.29

2011

2012

1
0.94

2010

1.45

2009

1.85

2008

Odds Ratio

2007

Cohort year

Covariates

(1.01,1.19)

(1.02,1.22)

Reference

(1.38,6.46)

(2.81,15.9)

Reference

(0.51,1.06)

(0.63,1.49)

Reference

(0.92,1.74)

Reference

Reference

(0.68,1.26)

Reference

(0.58,2.88)

(0.42,2.11)

(0.45,2.25)

(0.65,3.22)

(0.77,4.42)

CI

Full Model

0.023

0.013

0.005

<.001

0.095

0.873

0.151

0.624

0.534

0.886

0.992

0.366

0.169

P value

1.05

1.7

0.82

0.95

1.31

0.93

1.27

1.03

1.12

1.56

1.99

Odds Ratio

N/A

N/A

Reference

(0.64,1.72)

(1.13,2.55)

Reference

(0.58,1.18)

(0.62,1.46)

Reference

(0.96,1.80)

Reference

Reference

(0.68,1.26)

Reference

(0.57,2.82)

(0.46,2.28)

(0.50,2.49)

(0.71,3.45)

(0.84,4.70)

CI

0.837

0.01

0.29

0.82

0.094

0.623

0.552

0.95

0.784

0.271

0.118

P value

Model Excluding OOP cost variables

Author Manuscript

Multivariable Logistic Model for Non-adherence

Author Manuscript
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West

0.84

Third quartile

0.97

Third quartile

Author Manuscript
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0.8
1.14

Second quartile
Third quartile
Fourth quartile

0.96

First quartile

Census tract % college in quartile

Fourth quartile

0.87

Second quartile

First quartile

Census tract % below poverty level in quartile
1

1.18

Second quartile

Fourth quartile

0.89

First quartile

Census tract median income in quartile

0.84

0.71

Midwest
South

0.85

0.96

Northeast

Region

Non-Metropolitan

Metropolitan

Urban/rural status

Odds Ratio

Author Manuscript

Covariates

Reference

(0.65,1.98)

(0.44,1.47)

(0.48,1.92)

Reference

(0.53,1.78)

(0.43,1.77)

(0.42,2.37)

Reference

(0.44,1.60)

(0.51,2.76)

(0.29,2.75)

Reference

(0.52,1.37)

(0.38,1.31)

(0.51,1.42)

Reference

(0.56,1.67)

CI

0.647

0.474

0.907

0.933

0.701

0.999

0.587

0.698

0.843

0.491

0.268

0.531

0.892

P value

1.2

0.84

1.02

1.03

0.91

1.03

0.83

1.16

0.87

0.89

0.76

0.86

0.94

Odds Ratio

Reference

(0.69,2.09)

(0.46,1.53)

(0.51,2.02)

Reference

(0.57,1.87)

(0.45,1.82)

(0.44,2.42)

Reference

(0.44,1.57)

(0.50,2.69)

(0.28,2.66)

Reference

(0.55,1.44)

(0.41,1.40)

(0.52,1.43)

Reference

(0.55,1.62)

CI

0.509

0.564

0.964

0.913

0.781

0.946

0.564

0.735

0.806

0.639

0.377

0.561

0.825

P value

Model Excluding OOP cost variables

Author Manuscript
Full Model

Shen et al.
Page 17

Author Manuscript

Author Manuscript
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0.27

2011
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Urban/rural status

Logged other drug payments

Logged TKI drug payment per month supply

Moderately subsidized

Heavily subsidized

Cost share group

Managed Care Organizations or Regional PPO or Employer Sponsored

Medicare prescription drug plan(PDP)

Plan type

Non-white

White

Race

older than 70

70 or younger

Age

Female

Male

Sex

1.06

1.32

3.51

1.09

0.97

0.86

1.04

0.33

2012

0.23

2010

0.7

2009

0.69

2008

Odds Ratio

2007

Cohort year

Covariates

(0.93,1.22)

(1.08,1.62)

Reference

(1.73,7.13)

Reference

(0.51,2.30)

(0.54,1.77)

Reference

(0.50,1.48)

Reference

Reference

(0.62,1.75)

Reference

(0.07,1.03)

(0.09,1.22)

(0.06,0.89)

(0.19,2.52)

(0.17,2.77)

CI

0.375

0.007

<.001

0.825

0.93

0.585

0.882

0.056

0.097

0.033

0.586

0.6

P value

Subgroup with subsidies

1.11

1.09

0.63

1.01

1.86

0.84

3.22

1.67

2.19

1.92

3.34

Odds Ratio

(0.99,1.24)

(0.98,1.20)

N/A

Reference

(0.40,0.99)

(0.50,2.02)

Reference

(1.20,2.88)

Reference

Reference

(0.56,1.27)

Reference

(1.01,10.3)

(0.51,5.42)

(0.68,7.02)

(0.59,6.22)

(0.95,11.8)

CI

0.071

0.1

0.046

0.98

0.006

0.419

0.048

0.396

0.187

0.279

0.061

P value

Subgroup without subsidies

Multivariable Logistic Model for Non-adherence in the Subgroups with and without Subsidies
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0.79
1.21

South

1.13
0.75

Second quartile
Third quartile

1.39
1.36

Second quartile
Third quartile

Author Manuscript
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1.37
1.7

Second quartile
Third quartile
Fourth quartile

1.88

First quartile

Census tract % college in quartile

Fourth quartile

1.24

First quartile

Census tract % below poverty level in quartile

Fourth quartile

0.71

First quartile

Census tract median income in quartile

West

1.21

Midwest

0.91

Odds Ratio

Northeast

Region

Non-Metropolitan

Metropolitan

Author Manuscript

Covariates

Reference

(0.64,4.52)

(0.47,3.98)

(0.57,6.27)

Reference

(0.53,3.49)

(0.46,4.25)

(0.29,5.43)

Reference

(0.22,2.51)

(0.26,4.93)

(0.11,4.53)

Reference

(0.54,2.71)

(0.26,2.39)

(0.44,3.30)

Reference

(0.39,2.14)

CI

0.289

0.558

0.302

0.527

0.56

0.771

0.636

0.875

0.716

0.639

0.678

0.711

0.834

P value

0.86

0.53

0.59

0.84

0.73

0.77

0.8

1.15

1.13

0.62

0.62

0.79

0.91

Odds Ratio

Reference

(0.43,1.74)

(0.24,1.16)

(0.24,1.46)

Reference

(0.37,1.90)

(0.28,1.94)

(0.25,2.39)

Reference

(0.36,1.81)

(0.38,3.47)

(0.25,5.16)

Reference

(0.32,1.21)

(0.28,1.36)

(0.42,1.49)

Reference

(0.42,2.00)

CI

0.682

0.11

0.255

0.678

0.533

0.653

0.596

0.808

0.873

0.163

0.234

0.474

0.82

P value

Subgroup without subsidies

Author Manuscript
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